MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561838 | Name: Amethopterin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amethopterin is a chemotherapy agent and immune system suppressant. It can treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.

Chemical Structure

Amethopterin
Amethopterin
CAS#60388-53-6

Theoretical Analysis

MedKoo Cat#: 561838

Name: Amethopterin

CAS#: 60388-53-6

Chemical Formula: C20H22N8O5

Exact Mass: 454.1713

Molecular Weight: 454.44

Elemental Analysis: C, 52.86; H, 4.88; N, 24.66; O, 17.60

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Amethopterin; DL-Amethopterin;
IUPAC/Chemical Name
2-[[4-[(2,4-Diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
InChi Key
FBOZXECLQNJBKD-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)
SMILES Code
O=C(O)C(NC(C1=CC=C(N(CC2=NC3=C(N)N=C(N)N=C3N=C2)C)C=C1)=O)CCC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 454.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Suzuki R. NK/T Cell Lymphoma: Updates in Therapy. Curr Hematol Malig Rep. 2018 Jan 24. doi: 10.1007/s11899-018-0430-5. [Epub ahead of print] Review. PubMed PMID: 29368155. 2: McDaniel BL, Bentley ML. The role of medications and their management in acute kidney injury. Integr Pharm Res Pract. 2015 May 18;4:21-29. doi: 10.2147/IPRP.S52930. eCollection 2015. Review. PubMed PMID: 29354517; PubMed Central PMCID: PMC5741024. 3: Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK476185/ PubMed PMID: 29356468. 4: Pradère B, Thibault C, Vetterlein MW, Leow JJ, Peyronnet B, Rouprêt M, Seisen T. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. Transl Androl Urol. 2017 Dec;6(6):1049-1059. doi: 10.21037/tau.2017.09.12. Review. PubMed PMID: 29354492; PubMed Central PMCID: PMC5760386. 5: Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Shachter J, Shapira-Frommer R, Markel G. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jan 13. pii: S1568-9972(18)30010-7. doi: 10.1016/j.autrev.2018.01.003. [Epub ahead of print] Review. PubMed PMID: 29341936. 6: Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci. 2018 Jan 16. doi: 10.17305/bjbms.2018.2792. [Epub ahead of print] Review. PubMed PMID: 29338679. 7: Millan NC, Pastrana A, Guitter MR, Zubizarreta PA, Monges MS, Felice MS. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res. 2018 Jan 2;65:86-93. doi: 10.1016/j.leukres.2017.12.010. [Epub ahead of print] Review. PubMed PMID: 29328996. 8: Yeganeh MH, Kheir MM, Shahi A, Parvizi J. Rheumatoid Arthritis, Disease Modifying Agents, and Periprosthetic Joint Infection: What Does a Joint Surgeon Need to Know? J Arthroplasty. 2017 Nov 23. pii: S0883-5403(17)31036-7. doi: 10.1016/j.arth.2017.11.031. [Epub ahead of print] Review. PubMed PMID: 29325724. 9: Lauvrak V, Norderhaug IN. Infection Preventive Interventions in Primary Total Hip Replacements [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK464841/ PubMed PMID: 29320057. 10: Arentz-Hansen H, Palm Ø, Natvig Norderhaug I, Klemp Gjertsen M, Nordvåg BY. Tumor Necrosis Factor (TNF) Inhibitors for Rheumatic Diseases (Part 2): A Systematic Review of Data From Registries and Safety Databases [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK464738/ PubMed PMID: 29319954. 11: Taddio A, Ferrara G, Insalaco A, Pardeo M, Gregori M, Finetti M, Pastore S, Tommasini A, Ventura A, Gattorno M. Dealing with Chronic Non-Bacterial Osteomyelitis: a practical approach. Pediatr Rheumatol Online J. 2017 Dec 29;15(1):87. doi: 10.1186/s12969-017-0216-7. Review. PubMed PMID: 29287595; PubMed Central PMCID: PMC5747935. 12: Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2. Review. PubMed PMID: 29271481. 13: Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Am J Clin Dermatol. 2017 Dec 19. doi: 10.1007/s40257-017-0337-2. [Epub ahead of print] Review. PubMed PMID: 29260411. 14: Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2017 Dec 14. doi: 10.1007/s10238-017-0479-9. [Epub ahead of print] Review. PubMed PMID: 29243035. 15: Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, Shapiro J. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018 Jan;78(1):15-24. doi: 10.1016/j.jaad.2017.04.1142. Review. PubMed PMID: 29241773. 16: Schneider-Burrus S, Arpa E, Kors C, Stavermann T, Sabat R, Kokolakis G. [Drug therapy of acne inversa]. Hautarzt. 2018 Jan;69(1):58-63. doi: 10.1007/s00105-017-4094-1. Review. German. PubMed PMID: 29234829. 17: Silva MF, Ribeiro C, Gonçalves VMF, Tiritan ME, Lima Á. Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review. Biomed Chromatogr. 2017 Dec 11. doi: 10.1002/bmc.4159. [Epub ahead of print] Review. PubMed PMID: 29226354. 18: Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):578-586. doi: 10.1182/asheducation-2017.1.578. Review. PubMed PMID: 29222307. 19: Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):565-577. doi: 10.1182/asheducation-2017.1.565. Review. PubMed PMID: 29222306. 20: Hough R, Vora A. Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment). Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):251-258. doi: 10.1182/asheducation-2017.1.251. Review. PubMed PMID: 29222263.